In previous clinical reports, 10% of KRAS mutant CRC exhibited disease control [28], and mutations in codon 13 (G13D) have been suggested to be more sensitive to cetuximab than mutations in codon 12 [29, 30]. The gene discussed is KRAS; the disease is colorectal carcinoma.